These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33389405)

  • 1. Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Kennard K; Buckley ME; Sizer LM; Larson S; Carter WB; Frazier TG; Carp NZ
    Breast Cancer Res Treat; 2021 Feb; 186(1):53-63. PubMed ID: 33389405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index, diabetes, and triple-negative breast cancer prognosis.
    Tait S; Pacheco JM; Gao F; Bumb C; Ellis MJ; Ma CX
    Breast Cancer Res Treat; 2014 Jul; 146(1):189-97. PubMed ID: 24869799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index and weight change in relation to triple-negative breast cancer survival.
    Bao PP; Cai H; Peng P; Gu K; Su Y; Shu XO; Zheng Y
    Cancer Causes Control; 2016 Feb; 27(2):229-36. PubMed ID: 26621544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of male triple negative breast cancer: A population-based study.
    Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
    Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.
    Gonzalez-Conchas GA; Rodriguez-Romo L; Hernandez-Barajas D; Gonzalez-Guerrero JF; Rodriguez-Fernandez IA; Verdines-Perez A; Templeton AJ; Ocana A; Seruga B; Tannock IF; Amir E; Vera-Badillo FE
    Cancer Treat Rev; 2018 Jan; 62():1-8. PubMed ID: 29126017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran.
    Mousavi SA; Kasaeian A; Pourkasmaee M; Ghavamzadeh A; Alimoghaddam K; Vaezi M; Kamranzadeh Fumani H; Babakhani D; Tavakoli S
    PLoS One; 2019; 14(1):e0208701. PubMed ID: 30608935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Metaplastic Breast Cancer Versus Triple-Negative Breast Cancer: A Propensity Score Matching Analysis.
    Tan Y; Yang B; Chen Y; Yan X
    World J Surg; 2023 Dec; 47(12):3192-3202. PubMed ID: 37709983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs.
    Fan Y; Ding X; Wang J; Ma F; Yuan P; Li Q; Zhang P; Xu B
    Int J Biol Markers; 2015 May; 30(2):e200-7. PubMed ID: 25953090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
    Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
    Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer.
    Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
    AJR Am J Roentgenol; 2017 Mar; 208(3):687-694. PubMed ID: 28004976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
    Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
    PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
    Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
    Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.